Gilead Sciences, Inc. (GILD) stock analysis

Healthcare · Drug Manufacturers - General

From the 10-K filed 2026-02-24

Business type: Franchise

How it makes money

It generates a substantial portion of its revenue from HIV treatments, including the Biktarvy regimen and the newly approved twice-yearly injectable Yeztugo.

Profit is primarily driven by a dominant portfolio of HIV therapies that has transitioned from complex multi-pill regimens to single-tablet regimens and long-acting injectables. These medications, such as Biktarvy (bictegravir/FTC/TAF) and Yeztugo (lenacapavir), are critical for both long-term infection management and pre-exposure prophylaxis.

The business model relies on the clinical adoption of its proprietary TAF-based combinations. Profitability is sensitive to the mix of patients moving to newer, patent-protected therapies as older formulations face generic competition.

What protects it: the moat

It protects Biktarvy earnings through patent litigation settlements that prevent generic versions from entering the U.S. market until April 1, 2036.

Management extended the expected exclusivity for its core HIV product, Biktarvy, by more than two years through legal settlements with generic manufacturers. These agreements provide a protected revenue window until April 1, 2036, significantly longer than the previous projection of December 2033.

This legal shield maintains the company's market share in the HIV treatment space against rivals by preventing lower-cost versions of its most prescribed fixed-dose combinations from entering the market.

What growth costs

It funds the development of oncology treatments by acquiring firms like Arcellx to gain control of investigational cell therapies for multiple myeloma.

To diversify beyond virology, the company invests heavily in its oncology pipeline through internal R&D and targeted acquisitions. The planned 2026 acquisition of Arcellx is a strategic move to gain full control of anitocabtagene autoleucel, a CAR T-cell therapy.

These growth efforts require significant capital for late-stage clinical trials and the maintenance of specialized manufacturing facilities in California, Maryland, and the Netherlands. Maintaining this pipeline is essential as it seeks to bring 10+ transformative therapies to market by 2030.

What could damage it

The personalized nature of cell therapies creates a risk where disruptions at third-party apheresis centers or logistics vendors cause permanent product loss.

Unlike mass-produced pharmaceuticals, oncology products like Yescarta and Tecartus depend on a fragile, circular supply chain where a patient's own white blood cells are collected, shipped, engineered, and returned. Any failure at third-party collection sites or specialized hospitals can result in the loss of a therapy batch.

Furthermore, FDA-mandated 'boxed warnings' regarding secondary malignancies for CAR T-cell therapies can impair physician confidence and payer reimbursement, attacking the growth potential of the company's oncology segment.

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

More on GILD

Other companies in Drug Manufacturers - General